Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 25, Issue 3, 1996, Pages 168-173

  Storgaard, M ^a   Jensen, M P ^a   Stengaard Pedersen, K ^a   Moller B K ^a   Andersen, P L ^a   Obel, N ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CD18 and CD11b expression; chemotaxis; superoxide anion generation

Indexed keywords

AUROTHIOMALATE; METHOTREXATE; SALAZOSULFAPYRIDINE; SUPEROXIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029893743     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749609080009     Document Type: Article

References (31)

1. Greenwald RA. Oxygen radicals, inflammation and arthritis: patophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991; 20: 219-40.
2. Cencetti A, De-Martino M, Graziani E, Bongi SM, Palermo C, Pavari E, Zoppi M. Superoxide anion production by circulating polymorphonuclear leucocytes in rheumatoid arthritis. Clin Rheumatol 1990; 9: 51-5.
3. Al Balla S, Johnston C, Davis P. The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation. Clin Exp Rheumatol 1990; 8: 41-5.
4. Pronai L, Ichikawa Y, Ichimori K, Nakazawa H, Arimori S. Association of enchanced superoxide generation by neutrophils with low superoxide scavenging activity of the peripheral blood, joint fluid, and their leukocyte components in rheumatoid arthritis: effects of slow-acting anti-rheumatic drugs and disease activity. Clin Exp Rheumatol 1991; 9: 149-55.
5. Biemond P, Swaak AJ, Penders JM, Beindorff CM, Koster JE. Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarhtritis: in vivo inhibition by the anti-rheumatic drug piroxicam due to interference with the activation of NADPH-oxidase. Ann Rheum Dis 1986; 45: 249-55.
6. Howe CB, Fordham JN, Brown KA, Currey HLF. Polymorphonuclear cell function in rheumatoid arthritis and in Felly's syndrome. Ann Rheum Dis 1981; 40: 370-5.
7. Wandall JH. Leucocyte function in patients with rheumatoid arthritis: quantitative in vivo leucocyte mobilisation and in-vitro functions of blood and exudate leucocytes. Ann Rheum Dis 1985; 44: 694-700.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. Borregaard N, Heiple JM, Simons ER, Clark RA. Subcellular localization of the b-cytochrome component of the human neutrophil oxidase: translocation during activation. J Cell Biol 1983; 97: 52-61.
10. 51Cr-labelling methods. Acta Pathol Microbiol Immunol Scand 1995; 103: 185-92.
11. Mege JL, Capo C, Bongrand P, Richard P, Roux H. Monocytes and granulocytes in rheumatoid arthritis (RA): phagocytic activity and superoxide union production. Clin Rheumatol 1985; 4: 433-40.
12. Chiu PL, Davis P, Wong K, Dasgupta M. Superoxide production in neutrophils of patients with rheumatoid arthritis and Felty's syndrome. J Rheumatol 1983; 10: 694-700.
13. Ozaki Y, Ohashi T, Niwa Y. Oxygen radical production by neutrophils from patients with bacterial infection and rheumatoid arthritis. Measurement of hydrogen peroxide may most accurately represent enhancement of oxygen radical production during infection. Inflammation 1986; 10: 119-30.
14. Suryaprabha P, Das UN, Ramesh G, Kumar KV, Kumar GS. Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. Prostaglandins Leukol Essent Fatty Acids 1991; 43: 251-5.
15. Sheja A, Forsgren A, Marsal L, Wollenheim F. Inhibition of in vivo leucocyte migration by NSAIDs. Clin Exp Rheumatol 1985; 3: 53-8.
16. Goddard DH, Kirk AP, Kirwan JR, Johnson GD, Holborow EJ. Impaired polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 151-6.
17. Hanlon SM, Panayi GS, Laurent R. Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis 1980; 39: 68-74.
18. Hilario MO, Goldenberg J, Atra E, Naspitz CK. Chemotaxis of leukocytes from peripheral blood of patients with juvenile rheumatoid arthritis (JRA). Allergol Immunopathol 1990; 18: 243-8.
19. Atlai WM, Ali MKH, Abu-Ghazalah LMA, Shams AH, Clark HW, Brown TM et al. Defective serum chemotactic capacity in rheumatoid arthritis. Ann Allergy 1983; 50: 266-70.
20. Graham GG, Dale MM. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes II. Evidence for the formation and biological activity of aurocyanide. Biochem Pharmacol 1990; 39: 1697-702.
21. Rudkowski R, Graham GG, Champion GD, Ziegler JB. The activation of gold complexes by cyanide produced by polymorphonuclcar leukocytes-1. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 1687-95.
22. Davis P, Johnston C. Effects of gold compounds on function of phagocytic cells. Inflammation 1986; 10: 311-20.
23. Melby K, Quie PG. Effects of methotrexate, ampicillin and gentamicin alone and in combination on the in vitro locomotion on human polymorphonuclear cells (PMN). Acta Pathol Microbiol Immunol Scand 1984; 92: 331-3.
24. Elmgreen J, Ahnfelt-Ronne I, Nielsen OH. Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway. Ann Rheum Dis 1989; 48: 134-8.
25. Kerwar SS, Oronsky AL. Methotrexate in rheumatoid arthritis: studies with animal models. Adv Enzyme Regul 1989; 29: 247-65.
26. O'Callaghan JW, Forrest MJ, Brooks PM. Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients. Rheumatol Int 1988; 8: 41-5.
27. Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a singleoral dose of methotrexate. Arthritis Rheum 1990; 33: 1149-55.
28. Porter DR, Capell HA. Sulphasalazine as a disease modifying anti-rheumatic drug. Clin Rheumatol 1990; 4: 535-51.
29. Wandall JH. Effects of sulphasalazine and its metabolites on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Aliment Pharmacol Ther 1991; 5: 609-19.
30. Humbria A, Diaz-Gonzalez F, Campanero MR, Arroyo AG, Laffon A, Gonzalez-Amaro R, Sanchez-Madrid F. Expression of L-selectin, CD43, and CD44 in synovial fluid neutrophils from patients with inflammatory joint diseases. Evidence for a soluble form of L-selectin in synovial fluid. Arthritis Rheum 1994; 37: 342-48.
31. Felzmann T, Gadd S, Majdic O, Mauer O, Petera P, Smolen J et al. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol 1991; 11: 205-12.